Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.17
ALRPRB.PFD's Cash-to-Debt is ranked lower than
89% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. ALRPRB.PFD: 0.17 )
Ranked among companies with meaningful Cash-to-Debt only.
ALRPRB.PFD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.14 Max: 1.88
Current: 0.17
0.08
1.88
Equity-to-Asset 0.32
ALRPRB.PFD's Equity-to-Asset is ranked lower than
85% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. ALRPRB.PFD: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
ALRPRB.PFD' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.49  Med: 0.35 Max: 0.77
Current: 0.32
-0.49
0.77
Debt-to-Equity 1.65
ALRPRB.PFD's Debt-to-Equity is ranked lower than
90% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. ALRPRB.PFD: 1.65 )
Ranked among companies with meaningful Debt-to-Equity only.
ALRPRB.PFD' s Debt-to-Equity Range Over the Past 10 Years
Min: -7.59  Med: 0.93 Max: 4.08
Current: 1.65
-7.59
4.08
Debt-to-EBITDA 13.68
ALRPRB.PFD's Debt-to-EBITDA is ranked lower than
97% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. ALRPRB.PFD: 13.68 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ALRPRB.PFD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -21.04  Med: 6.78 Max: 13.68
Current: 13.68
-21.04
13.68
Piotroski F-Score: 4
Altman Z-Score: 0.80
Beneish M-Score: -2.95
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -3.00
ALRPRB.PFD's Operating Margin % is ranked lower than
54% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. ALRPRB.PFD: -3.00 )
Ranked among companies with meaningful Operating Margin % only.
ALRPRB.PFD' s Operating Margin % Range Over the Past 10 Years
Min: -44.13  Med: 3.88 Max: 7.6
Current: -3
-44.13
7.6
Net Margin % -10.71
ALRPRB.PFD's Net Margin % is ranked lower than
56% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. ALRPRB.PFD: -10.71 )
Ranked among companies with meaningful Net Margin % only.
ALRPRB.PFD' s Net Margin % Range Over the Past 10 Years
Min: -47.2  Med: -3.08 Max: 8.29
Current: -10.71
-47.2
8.29
ROE % -14.34
ALRPRB.PFD's ROE % is ranked lower than
55% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. ALRPRB.PFD: -14.34 )
Ranked among companies with meaningful ROE % only.
ALRPRB.PFD' s ROE % Range Over the Past 10 Years
Min: -34.13  Med: -4.53 Max: 9.2
Current: -14.34
-34.13
9.2
ROA % -4.38
ALRPRB.PFD's ROA % is ranked higher than
50% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. ALRPRB.PFD: -4.38 )
Ranked among companies with meaningful ROA % only.
ALRPRB.PFD' s ROA % Range Over the Past 10 Years
Min: -15.33  Med: -1.1 Max: 3.23
Current: -4.38
-15.33
3.23
ROC (Joel Greenblatt) % -7.31
ALRPRB.PFD's ROC (Joel Greenblatt) % is ranked higher than
52% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. ALRPRB.PFD: -7.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALRPRB.PFD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -169.64  Med: 9.35 Max: 22.95
Current: -7.31
-169.64
22.95
3-Year Revenue Growth Rate -5.10
ALRPRB.PFD's 3-Year Revenue Growth Rate is ranked lower than
70% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. ALRPRB.PFD: -5.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALRPRB.PFD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.6  Med: 8.2 Max: 73
Current: -5.1
-8.6
73
3-Year EBITDA Growth Rate -17.50
ALRPRB.PFD's 3-Year EBITDA Growth Rate is ranked lower than
81% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. ALRPRB.PFD: -17.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALRPRB.PFD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -9.1 Max: 51.7
Current: -17.5
0
51.7
3-Year EPS without NRI Growth Rate -23.10
ALRPRB.PFD's 3-Year EPS without NRI Growth Rate is ranked lower than
83% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. ALRPRB.PFD: -23.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALRPRB.PFD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -23.1 Max: 57.2
Current: -23.1
0
57.2
GuruFocus has detected 5 Warning Signs with Alere Inc ALRPRB.PFD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALRPRB.PFD's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

ALRPRB.PFD Guru Trades in

ALRPRB.PFD Guru Trades in

ALRPRB.PFD Guru Trades in

Q4 2017

ALRPRB.PFD Guru Trades in Q4 2017

Private Capital Sold Out
Pioneer Investments Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ALRPRB.PFD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Alere Inc does not have enough historical financial data to display Peter Lynch Chart.

Preferred stocks of Alere Inc

SymbolPriceYieldDescription
ALRPRB.PFD402.002.993 % Conv Perp Pfd Shs Series -B-

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:SHSE:603658, NAS:BRKR, NAS:SYNH, NYSE:CRL, MIL:DIA, NAS:NEOG, NAS:PRAH, NAS:FMI, XTER:AFX, NAS:EXAS, BSP:DASA3, NAS:ICLR, BSP:FLRY3, NAS:DXCM, SZSE:300463, TSE:4544, SHSE:603882, SZSE:300482, NAS:QDEL, SZSE:300244 » details
Traded in other countries:IM5.Germany,
Headquarter Location:USA
Alere Inc provides rapid diagnostics at the point of care, with a focus on cardio metabolic disease, infectious disease and toxicology. The Company's business segments are professional diagnostics, consumer diagnostics, and corporate and other.

Alere, Inc. develops rapid point-of-care diagnostic devices in cardiology, infectious disease, toxicology, diabetes, oncology, and women's health. North America accounts for the largest portion of the firm's revenue (55%), followed by Europe (19%), Asia-Pacific (14%), and the rest of the world (12%). Alere's headquarters are in Waltham, Massachusetts.

Top Ranked Articles about Alere Inc

Prem Watsa Trims IBM, Berkshire Hathaway The guru’s largest sales of the 4th quarter
Prem Watsa (Trades, Portfolio), founder, chairman and CEO of Fairfax Financial Holdings,  sold shares of the following stocks during the fourth quarter. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 23.36
ALRPRB.PFD's Forward PE Ratio is ranked higher than
52% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALRPRB.PFD: 23.36 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 309.03
ALRPRB.PFD's Price-to-Owner-Earnings is ranked lower than
97% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.75 vs. ALRPRB.PFD: 309.03 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ALRPRB.PFD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.13  Med: 22.34 Max: 554.86
Current: 309.03
9.13
554.86
PB Ratio 3.86
ALRPRB.PFD's PB Ratio is ranked higher than
51% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. ALRPRB.PFD: 3.86 )
Ranked among companies with meaningful PB Ratio only.
ALRPRB.PFD' s PB Ratio Range Over the Past 10 Years
Min: 0.42  Med: 1.69 Max: 3.86
Current: 3.86
0.42
3.86
PS Ratio 1.91
ALRPRB.PFD's PS Ratio is ranked higher than
73% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. ALRPRB.PFD: 1.91 )
Ranked among companies with meaningful PS Ratio only.
ALRPRB.PFD' s PS Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.41 Max: 4.22
Current: 1.91
0.52
4.22
Price-to-Free-Cash-Flow 131.76
ALRPRB.PFD's Price-to-Free-Cash-Flow is ranked lower than
88% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. ALRPRB.PFD: 131.76 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALRPRB.PFD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.03  Med: 19.89 Max: 131.76
Current: 131.76
7.03
131.76
Price-to-Operating-Cash-Flow 47.61
ALRPRB.PFD's Price-to-Operating-Cash-Flow is ranked lower than
81% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. ALRPRB.PFD: 47.61 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALRPRB.PFD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.63  Med: 11.82 Max: 48.6
Current: 47.61
4.63
48.6
EV-to-EBITDA 35.26
ALRPRB.PFD's EV-to-EBITDA is ranked lower than
78% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. ALRPRB.PFD: 35.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALRPRB.PFD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -173.6  Med: 13.55 Max: 87.3
Current: 35.26
-173.6
87.3
EV-to-Revenue 3.21
ALRPRB.PFD's EV-to-Revenue is ranked higher than
62% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. ALRPRB.PFD: 3.21 )
Ranked among companies with meaningful EV-to-Revenue only.
ALRPRB.PFD' s EV-to-Revenue Range Over the Past 10 Years
Min: 2  Med: 2.7 Max: 6.1
Current: 3.21
2
6.1
Current Ratio 2.04
ALRPRB.PFD's Current Ratio is ranked lower than
60% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. ALRPRB.PFD: 2.04 )
Ranked among companies with meaningful Current Ratio only.
ALRPRB.PFD' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.78 Max: 3.42
Current: 2.04
0.7
3.42
Quick Ratio 1.54
ALRPRB.PFD's Quick Ratio is ranked lower than
66% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. ALRPRB.PFD: 1.54 )
Ranked among companies with meaningful Quick Ratio only.
ALRPRB.PFD' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 1.36 Max: 2.89
Current: 1.54
0.46
2.89
Days Inventory 95.83
ALRPRB.PFD's Days Inventory is ranked lower than
56% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. ALRPRB.PFD: 95.83 )
Ranked among companies with meaningful Days Inventory only.
ALRPRB.PFD' s Days Inventory Range Over the Past 10 Years
Min: 80.56  Med: 93.18 Max: 104.46
Current: 95.83
80.56
104.46
Days Sales Outstanding 59.13
ALRPRB.PFD's Days Sales Outstanding is ranked higher than
60% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. ALRPRB.PFD: 59.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALRPRB.PFD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 59.13  Med: 67.28 Max: 79.93
Current: 59.13
59.13
79.93
Days Payable 65.70
ALRPRB.PFD's Days Payable is ranked higher than
53% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. ALRPRB.PFD: 65.70 )
Ranked among companies with meaningful Days Payable only.
ALRPRB.PFD' s Days Payable Range Over the Past 10 Years
Min: 45.36  Med: 53.06 Max: 65.7
Current: 65.7
45.36
65.7

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.99
ALRPRB.PFD's Dividend Yield % is ranked lower than
99.99% of the 121 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.81 vs. ALRPRB.PFD: 2.99 )
Ranked among companies with meaningful Dividend Yield % only.
ALRPRB.PFD' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 4.66
Current: 2.99
0
4.66
Forward Dividend Yield % 2.99
ALRPRB.PFD's Forward Dividend Yield % is ranked lower than
99.99% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. ALRPRB.PFD: 2.99 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.99
ALRPRB.PFD's 5-Year Yield-on-Cost % is ranked lower than
87% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. ALRPRB.PFD: 2.99 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ALRPRB.PFD' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 4.66
Current: 2.99
0
4.66
3-Year Average Share Buyback Ratio -2.00
ALRPRB.PFD's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. ALRPRB.PFD: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALRPRB.PFD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -60.8  Med: -3.4 Max: 19.3
Current: -2
-60.8
19.3

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -0.72
ALRPRB.PFD's Earnings Yield (Greenblatt) % is ranked higher than
51% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. ALRPRB.PFD: -0.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALRPRB.PFD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -19.4  Med: 1.3 Max: 3.1
Current: -0.72
-19.4
3.1
Forward Rate of Return (Yacktman) % -7.16
ALRPRB.PFD's Forward Rate of Return (Yacktman) % is ranked lower than
90% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.45 vs. ALRPRB.PFD: -7.16 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ALRPRB.PFD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -7.2  Med: 3.6 Max: 10.8
Current: -7.16
-7.2
10.8

More Statistics

52-Week Range $292.00 - 402.05

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}